Literature DB >> 14678644

Recombinant anti-botulinum neurotoxin A single-chain variable fragment antibody generated using a phage display system.

David C W Mah1, Wei-Gang Hu, J Kelly Pon, Saad A Masri, R Elaine Fulton, Paul L Monette, Les P Nagata.   

Abstract

A recombinant single-chain fragment variable antibody (scFv) to botulinum A neurotoxin (BoNT/A) was developed. BALB/C mice were immunized with BoNT/A. Splenomic RNA was isolated from the hyperimmune mice and used to prepare a cDNA library, from which the variable regions of the heavy and light chain antibody genes were generated and connected by a DNA linker. The resulting scFv genes were cloned into the phagemid vector pCANTAB5 in order to construct phage display scFv libraries. Individual anti-BoNT/A phage clones were isolated from the phage display libraries by immunoaffinity selection using immobilized BoNT/A and further evaluated by enzyme-linked immunosorbant assay, immunoprecipitation and Western blotting. Forty-eight clones were found to be BoNT/A-reactive. The most reactive clone, designated D12, was selected for further study. The scFv gene of D12 was subcloned into a Pichia pastoris vector, and expression in yeast was evaluated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678644     DOI: 10.1089/153685903322538791

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  2 in total

1.  Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.

Authors:  Suzanne R Kalb; Consuelo Garcia-Rodriguez; Jianlong Lou; Jakub Baudys; Theresa J Smith; James D Marks; Leonard A Smith; James L Pirkle; John R Barr
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

2.  Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.

Authors:  Suzanne R Kalb; Jianlong Lou; Consuelo Garcia-Rodriguez; Isin N Geren; Theresa J Smith; Hercules Moura; James D Marks; Leonard A Smith; James L Pirkle; John R Barr
Journal:  PLoS One       Date:  2009-04-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.